Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Impact · against what's priced in

Immuneering's stock is likely to see a positive catalyst following the report of significantly improved 12-month overall survival (64% vs 35% benchmark) in first-line pancreatic cancer. The confirmed cash runway into 2029 and the mid-2026 start date for the pivotal Phase 3 trial provide strong fundamental de-risking.

IMRX+0.70

No priced-in read yet